TY - JOUR
T1 - Longitudinal prognostication in retroperitoneal sarcoma survivors
T2 - Development and external validation of two dynamic nomograms
AU - Callegaro, Dario
AU - Barretta, Francesco
AU - Swallow, Carol J.
AU - Strauss, Dirk C.
AU - Bonvalot, Sylvie
AU - Honorè, Charles
AU - Stoeckle, Eberhard
AU - van Coevorden, Frits
AU - Haas, Rick
AU - Rutkowski, Piotr
AU - Schrage, Yvonne
AU - Fairweather, Mark
AU - Conti, Lorenzo
AU - Vassos, Nikolaos
AU - Gladdy, Rebecca A.
AU - Ng, Deanna
AU - van Houdt, Winan J.
AU - Miceli, Rosalba
AU - Raut, Chandrajit P.
AU - Gronchi, Alessandro
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Purpose: The aim of this study was to create and validate dynamic nomograms to predict overall survival (OS) and disease-free survival (DFS) at different time points during follow-up in patients who had undergone resection of primary retroperitoneal sarcoma (RPS). Methods: Patients with primary RPS operated upon between 2002 and 2017 at four and six referral centres comprised the development and external validation cohorts, respectively. Landmark analysis and multivariable Cox models were used to develop dynamic nomograms. Variables were selected using two backward procedures based on the Akaike information criterion. The prediction window was fixed at 5 years. Nomogram performances were tested in terms of calibration and discrimination on the development and validation cohorts. Results: Development and validation cohorts totalled 1357 and 487 patients (OS analysis), and 1309 and 452 patients (DFS analysis), respectively. The final OS model included age, landmark time (TLM), tumour grade, completeness of resection and occurrence of local/distant recurrence. The final DFS model included TLM, histologic subtype, tumour size, tumour grade, multifocality and the interaction terms between TLM and size, grade and multifocality. For OS, Harrell C indices were higher than 0.7 in both cohorts, indicating very good discriminative capability. For DFS, Harrell C indices were between 0.64 and 0.72 in the development cohort and 0.62 and 0.68 in the validation cohort. Calibration plots showed good agreement between predicted and observed outcomes. Conclusion: Validated nomograms are available to predict the 5-year OS and DFS probability at different time points throughout the first 5 years of follow-up in RPS survivors.
AB - Purpose: The aim of this study was to create and validate dynamic nomograms to predict overall survival (OS) and disease-free survival (DFS) at different time points during follow-up in patients who had undergone resection of primary retroperitoneal sarcoma (RPS). Methods: Patients with primary RPS operated upon between 2002 and 2017 at four and six referral centres comprised the development and external validation cohorts, respectively. Landmark analysis and multivariable Cox models were used to develop dynamic nomograms. Variables were selected using two backward procedures based on the Akaike information criterion. The prediction window was fixed at 5 years. Nomogram performances were tested in terms of calibration and discrimination on the development and validation cohorts. Results: Development and validation cohorts totalled 1357 and 487 patients (OS analysis), and 1309 and 452 patients (DFS analysis), respectively. The final OS model included age, landmark time (TLM), tumour grade, completeness of resection and occurrence of local/distant recurrence. The final DFS model included TLM, histologic subtype, tumour size, tumour grade, multifocality and the interaction terms between TLM and size, grade and multifocality. For OS, Harrell C indices were higher than 0.7 in both cohorts, indicating very good discriminative capability. For DFS, Harrell C indices were between 0.64 and 0.72 in the development cohort and 0.62 and 0.68 in the validation cohort. Calibration plots showed good agreement between predicted and observed outcomes. Conclusion: Validated nomograms are available to predict the 5-year OS and DFS probability at different time points throughout the first 5 years of follow-up in RPS survivors.
KW - Dynamic nomogram
KW - Landmark analysis
KW - Prognosis
KW - Retroperitoneal sarcoma
KW - Soft tissue sarcoma
KW - Survivor
UR - http://www.scopus.com/inward/record.url?scp=85115207164&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2021.08.008
DO - 10.1016/j.ejca.2021.08.008
M3 - Article
C2 - 34555648
AN - SCOPUS:85115207164
SN - 0959-8049
VL - 157
SP - 291
EP - 300
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -